Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

GlobeNewswire November 18, 2024

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

GlobeNewswire November 14, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile November 12, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

Accesswire November 12, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Business Wire November 12, 2024

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PR Newswire November 12, 2024

FINAL REMINDER ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Allarity Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit!

Accesswire November 12, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile November 11, 2024

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Accesswire November 11, 2024

DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Accesswire November 11, 2024

FINAL ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Allarity Therapeutics, Inc. Investors to Join the Class Action Lawsuit!

Accesswire November 11, 2024

ALLR FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action - ALLR

Newsfile November 10, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

PR Newswire November 10, 2024

The Schall Law Firm Urges Shareholders In Allarity Therapeutics, Inc. To Join A Securities Fraud Case

Accesswire November 10, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile November 10, 2024

ALLR Shareholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

Accesswire November 10, 2024

ALLR DEADLINE ALERT: TOP RANKED ROSEN LAW FIRM Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important November 12 Deadline in Securities Class Action - ALLR

Newsfile November 9, 2024

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

Accesswire November 9, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile November 9, 2024

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Business Wire November 8, 2024